NANOBIOTIX (EPA:NANO)

BRIEF

published on 11/11/2025 at 22:20, 4 months 14 days ago

Nanobiotix will participate in the Jefferies London Healthcare conference

Biotechnology Oncology NANOBIOTIX Nanoparticles Jefferies Conference
PRESS RELEASE

published on 11/11/2025 at 22:15, 4 months 14 days ago

NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Nanobiotix to participate in Jefferies London Healthcare Conference on Nov 17, 2025, with company management as presenters. Webcast available. Learn about Nanobiotix and its disruptive therapeutic approaches

Webcast Nanotechnology NANOBIOTIX Therapeutic Approaches Jefferies London Healthcare Conference
BRIEF

published on 10/31/2025 at 08:05, 4 months 26 days ago

Nanobiotix Secures $71 Million Agreement with HealthCare Royalty

Long-term Growth HealthCare Royalty NANOBIOTIX Royalty Agreement Oncology Development
PRESS RELEASE

published on 10/31/2025 at 08:00, 4 months 26 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
BRIEF

published on 10/01/2025 at 22:20, 5 months 24 days ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
PRESS RELEASE

published on 10/01/2025 at 22:15, 5 months 24 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
BRIEF

published on 09/30/2025 at 22:20, 5 months 25 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 5 months 25 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
BRIEF

published on 09/30/2025 at 00:35, 5 months 26 days ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)
PRESS RELEASE

published on 09/30/2025 at 00:30, 5 months 26 days ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025

Published on 03/26/2026 at 21:00, 42 minutes ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 42 minutes ago

Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours 22 minutes ago

ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 14:05, 7 hours 37 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 8 hours 42 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 53 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours 21 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 2 hours 28 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 2 hours 32 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:57, 2 hours 44 minutes ago

DSH-Director/PDMR Shareholding

View all EQS

Published on 03/26/2026 at 18:17, 3 hours 25 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 17:45, 3 hours 57 minutes ago

Cegedim: profitability continues to improve
Published on 03/26/2026 at 08:57, 12 hours 44 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 14 hours 12 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 1 day 2 hours ago

LNA SANTE : 2025 Annual Results

View all LES ECHOS COMFI WIRE

News